pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·1h ago·1 min read
save

This week in charts: Biotech investors’ China bets are already paying off

Nov 20, 2026·read at BioPharma Dive ↗

This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.

source

Reporting by BioPharma Dive.

read at BioPharma Dive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 19h agoSanofi gains FDA clearance for Gaucher disease pillBioPharma Dive
  • 20h agoChina could ‘corner’ biopharma sector with new plan, US panel warnsBioPharma Dive
  • 22h agoWith FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseBioPharma Dive
  • 1d ago‘Selling and marketing snake oil’: The debate over compounded GLP-1sBioPharma Dive
  • 1d agoWhite House pulls nomination for FDA nominee OvertonBioPharma Dive